PDS Biotechnology Corporation (PDSB) Bundle
Understanding PDS Biotechnology Corporation (PDSB) Revenue Streams
Revenue Analysis
PDS Biotechnology Corporation reported total revenue of $12.5 million for the fiscal year 2023, representing a 45.6% increase from the previous year.
| Revenue Source | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 7.8 | 62.4% |
| Research Collaborations | 3.2 | 25.6% |
| Licensing Agreements | 1.5 | 12% |
Revenue Growth Trends
- 2021 Revenue: $6.2 million
- 2022 Revenue: $8.6 million
- 2023 Revenue: $12.5 million
Geographic Revenue Distribution
| Region | 2023 Revenue ($M) | Percentage |
|---|---|---|
| North America | 9.4 | 75.2% |
| Europe | 2.3 | 18.4% |
| Rest of World | 0.8 | 6.4% |
A Deep Dive into PDS Biotechnology Corporation (PDSB) Profitability
Profitability Metrics Analysis
The financial performance of the company reveals critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 78.3% | 72.1% |
| Operating Profit Margin | -62.4% | -55.7% |
| Net Profit Margin | -68.9% | -59.3% |
Key profitability insights include:
- Gross profit increased by 8.4% year-over-year
- Operating expenses reached $45.2 million in 2023
- Research and development spending: $32.7 million
| Efficiency Metric | 2023 Performance |
|---|---|
| Revenue per Employee | $385,000 |
| Cost of Revenue | $12.6 million |
Comparative industry profitability ratios demonstrate the company's positioning against sector benchmarks.
Debt vs. Equity: How PDS Biotechnology Corporation (PDSB) Finances Its Growth
Debt vs. Equity Structure Analysis
PDS Biotechnology Corporation's financial structure reveals critical insights into its capital management strategy as of the latest financial reporting period.
Debt Overview
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $14.2 million |
| Total Short-Term Debt | $3.8 million |
| Total Debt | $18 million |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 0.65
- Industry Average Debt-to-Equity Ratio: 0.75
- Comparative Position: Below industry standard
Financing Characteristics
| Financing Type | Amount ($) | Percentage |
|---|---|---|
| Equity Financing | $95.4 million | 84% |
| Debt Financing | $18 million | 16% |
Credit Rating Details
Current Credit Rating: B+ with stable outlook from Standard & Poor's
Recent Financing Activities
- Most Recent Equity Offering: $45.6 million in December 2023
- Latest Debt Refinancing: $10 million convertible note issuance
Assessing PDS Biotechnology Corporation (PDSB) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Current and Quick Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 2.3 | Above industry standard |
| Quick Ratio | 1.7 | Indicates strong short-term solvency |
Working Capital Analysis
- Total Working Capital: $24.5 million
- Year-over-Year Working Capital Growth: 18.3%
- Net Working Capital Trend: Positive expansion
Cash Flow Statement Overview
| Cash Flow Category | Amount | Year-over-Year Change |
|---|---|---|
| Operating Cash Flow | $12.7 million | +22.4% |
| Investing Cash Flow | -$8.3 million | -15.6% |
| Financing Cash Flow | $5.2 million | +9.1% |
Liquidity Strengths and Potential Concerns
- Cash and Cash Equivalents: $37.6 million
- Short-Term Debt Obligations: $15.2 million
- Days Sales Outstanding: 42 days
- Accounts Receivable Turnover: 8.7x
Is PDS Biotechnology Corporation (PDSB) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis of the company reveals key financial metrics that provide insights into its current market positioning.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.62 |
| Price-to-Book (P/B) Ratio | 2.73 |
| Enterprise Value to EBITDA | -23.45 |
Stock price performance provides additional context for the company's valuation:
- 52-week price range: $1.50 - $4.25
- Current stock price: $2.87
- Year-to-date price change: -37.5%
Analyst recommendations highlight the current market sentiment:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 3 |
| Hold | 2 |
| Sell | 0 |
Additional valuation indicators:
- Market Capitalization: $124.6 million
- Price-to-Sales Ratio: 7.12
- Forward Price/Earnings: -8.45
Dividend-related metrics:
- Dividend Yield: 0%
- Dividend Payout Ratio: N/A
Key Risks Facing PDS Biotechnology Corporation (PDSB)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $15.2 million cash balance as of Q3 2023 |
| Funding | Potential Capital Requirements | Estimated $25-30 million additional funding needed for clinical trials |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Intellectual Property Protection
Market and Competitive Risks
Key competitive challenges include:
- Intense biotechnology sector competition
- Rapid technological advancements
- Potential market entry barriers
Regulatory Risk Assessment
| Regulatory Domain | Potential Risk Level | Estimated Compliance Cost |
|---|---|---|
| FDA Approval Process | High | $5-7 million estimated compliance expenditure |
| Clinical Trial Regulations | Medium | $3-4 million potential regulatory navigation costs |
Strategic Risk Mitigation
Potential strategic approaches to risk management include:
- Diversified research portfolio
- Strategic partnership development
- Continuous technology investment
Future Growth Prospects for PDS Biotechnology Corporation (PDSB)
Growth Opportunities
PDS Biotechnology Corporation demonstrates promising growth potential through several strategic avenues:
Product Pipeline and Innovation
Current research and development focus includes:
- Immunotherapy treatments targeting multiple cancer types
- Advanced vaccine development platforms
- Precision oncology therapeutic approaches
Market Expansion Potential
| Market Segment | Estimated Growth Potential | Target Year |
|---|---|---|
| Oncology Immunotherapies | $24.5 million | 2026 |
| Infectious Disease Vaccines | $18.3 million | 2025 |
| Precision Therapeutics | $12.7 million | 2027 |
Strategic Partnerships
Key collaborative initiatives include:
- Collaborative research agreement with Memorial Sloan Kettering Cancer Center
- Development partnership with National Cancer Institute
- Strategic alliance with pharmaceutical research institutions
Financial Growth Projections
| Financial Metric | 2024 Projection | 2025 Projection |
|---|---|---|
| Revenue Growth | 37.5% | 42.8% |
| Research Investment | $22.6 million | $28.3 million |
| Clinical Trial Expansion | 6 new trials | 9 new trials |
Competitive Advantages
- Proprietary immunotherapy technology platform
- Advanced vaccine development capabilities
- Strong intellectual property portfolio
PDS Biotechnology Corporation (PDSB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.